Cellular Immunotherapy in Lymphoma: Beyond CART Cells

摘要: Cellular immunotherapy has been rapidly evolving and increasingly utilized in the management of relapsed refractory lymphoma. CD19-specific chimeric antigen receptor T cells (CARTs) have achieved impressive results pivotal clinical trials. Although CART development continues, these products fundamental limitations that may make them less desirable particular settings. For example, CARTs can only target cell surface antigens thus are incapable targeting intracellular tumor-associated proteins. In contrast to CARTs, conventional receptors (TCR) allow any cellular antigen, including proteins, since they interact with peptides presented by MHC I II molecules. recognizing EBV through native TCRs successfully employed for treatment prophylaxis EBV-associated lymphomas, post-transplant lymphoproliferative disorder. Currently, transgenic TCR-transduced nonviral tumor remain experimental but, if successful, could become an invaluable therapy option. Because manufacturing process autologous products, other tumor-specific cells, takes several weeks, patients often need bridging maintain disease control, which be challenging. Novel platforms, such as genetically modified NK NKT amenable allogeneic use production a readily available, “off-the-shelf” product. As therapies beyond continue grow, available therapeutic options lymphoma expected expand further.